P949: A PHASE 2 TRIAL OF ELRANATAMAB, A B-CELL MATURATION ANTIGEN (BCMA)-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: INITIAL SAFETY RESULTS FOR MAGNETISMM-3
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-06-01
|
| Series: | HemaSphere |
| Online Access: | http://journals.lww.com/10.1097/01.HS9.0000846664.78859.dd |
| _version_ | 1797281786525384704 |
|---|---|
| author | A. M. Lesokhin B. Arnulf R. Niesvizky M. Mohty N. J. Bahlis M. H. Tomasson P. Rodrίguez-Otero H. Quach N. S. Raje S. Iida M.-S. Raab A. Czibere S. Sullivan E. Leip A. Viqueira X. Leleu |
| author_facet | A. M. Lesokhin B. Arnulf R. Niesvizky M. Mohty N. J. Bahlis M. H. Tomasson P. Rodrίguez-Otero H. Quach N. S. Raje S. Iida M.-S. Raab A. Czibere S. Sullivan E. Leip A. Viqueira X. Leleu |
| author_sort | A. M. Lesokhin |
| collection | DOAJ |
| first_indexed | 2024-03-07T17:02:28Z |
| format | Article |
| id | doaj.art-f712e85bfd2c4e67907c75060d9796b6 |
| institution | Directory Open Access Journal |
| issn | 2572-9241 |
| language | English |
| last_indexed | 2024-03-07T17:02:28Z |
| publishDate | 2022-06-01 |
| publisher | Wiley |
| record_format | Article |
| series | HemaSphere |
| spelling | doaj.art-f712e85bfd2c4e67907c75060d9796b62024-03-03T03:19:42ZengWileyHemaSphere2572-92412022-06-01683984010.1097/01.HS9.0000846664.78859.dd202206003-00839P949: A PHASE 2 TRIAL OF ELRANATAMAB, A B-CELL MATURATION ANTIGEN (BCMA)-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: INITIAL SAFETY RESULTS FOR MAGNETISMM-3A. M. Lesokhin0B. Arnulf1R. Niesvizky2M. Mohty3N. J. Bahlis4M. H. Tomasson5P. Rodrίguez-Otero6H. Quach7N. S. Raje8S. Iida9M.-S. Raab10A. Czibere11S. Sullivan12E. Leip13A. Viqueira14X. Leleu151 Division of Hematology and Oncology, Memorial Sloan Kettering Cancer Center/Weill Cornell Medical College, New York, United States of America2 Hôpital Saint-Louis, Paris, France3 Weill Cornell Medical College - New York Presbyterian Hospital, New York, United States of America4 Sorbonne University, Hôpital Saint-Antoine, and INSERM UMRs938, Paris, France5 Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, Canada6 Holden Comprehensive Cancer Center, University of Iowa, Iowa City, United States of America7 Clinica Universidad de Navarra, Madrid, Spain8 University of Melbourne, Melbourne, Australia9 Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, United States of America10 Department of Hematology & Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan11 Heidelberg Myeloma Center, Department of Hematology/Oncology, Heidelberg University Hospital, Heidelberg, Germany12 Pfizer Inc, Cambridge, United States of America12 Pfizer Inc, Cambridge, United States of America12 Pfizer Inc, Cambridge, United States of America13 Pfizer SLU, Madrid, Spain14 Centre Hospitalier Universitaire de Poitiers, Poitiers, Francehttp://journals.lww.com/10.1097/01.HS9.0000846664.78859.dd |
| spellingShingle | A. M. Lesokhin B. Arnulf R. Niesvizky M. Mohty N. J. Bahlis M. H. Tomasson P. Rodrίguez-Otero H. Quach N. S. Raje S. Iida M.-S. Raab A. Czibere S. Sullivan E. Leip A. Viqueira X. Leleu P949: A PHASE 2 TRIAL OF ELRANATAMAB, A B-CELL MATURATION ANTIGEN (BCMA)-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: INITIAL SAFETY RESULTS FOR MAGNETISMM-3 HemaSphere |
| title | P949: A PHASE 2 TRIAL OF ELRANATAMAB, A B-CELL MATURATION ANTIGEN (BCMA)-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: INITIAL SAFETY RESULTS FOR MAGNETISMM-3 |
| title_full | P949: A PHASE 2 TRIAL OF ELRANATAMAB, A B-CELL MATURATION ANTIGEN (BCMA)-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: INITIAL SAFETY RESULTS FOR MAGNETISMM-3 |
| title_fullStr | P949: A PHASE 2 TRIAL OF ELRANATAMAB, A B-CELL MATURATION ANTIGEN (BCMA)-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: INITIAL SAFETY RESULTS FOR MAGNETISMM-3 |
| title_full_unstemmed | P949: A PHASE 2 TRIAL OF ELRANATAMAB, A B-CELL MATURATION ANTIGEN (BCMA)-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: INITIAL SAFETY RESULTS FOR MAGNETISMM-3 |
| title_short | P949: A PHASE 2 TRIAL OF ELRANATAMAB, A B-CELL MATURATION ANTIGEN (BCMA)-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: INITIAL SAFETY RESULTS FOR MAGNETISMM-3 |
| title_sort | p949 a phase 2 trial of elranatamab a b cell maturation antigen bcma cd3 bispecific antibody in patients with relapsed refractory multiple myeloma initial safety results for magnetismm 3 |
| url | http://journals.lww.com/10.1097/01.HS9.0000846664.78859.dd |
| work_keys_str_mv | AT amlesokhin p949aphase2trialofelranatamababcellmaturationantigenbcmacd3bispecificantibodyinpatientswithrelapsedrefractorymultiplemyelomainitialsafetyresultsformagnetismm3 AT barnulf p949aphase2trialofelranatamababcellmaturationantigenbcmacd3bispecificantibodyinpatientswithrelapsedrefractorymultiplemyelomainitialsafetyresultsformagnetismm3 AT rniesvizky p949aphase2trialofelranatamababcellmaturationantigenbcmacd3bispecificantibodyinpatientswithrelapsedrefractorymultiplemyelomainitialsafetyresultsformagnetismm3 AT mmohty p949aphase2trialofelranatamababcellmaturationantigenbcmacd3bispecificantibodyinpatientswithrelapsedrefractorymultiplemyelomainitialsafetyresultsformagnetismm3 AT njbahlis p949aphase2trialofelranatamababcellmaturationantigenbcmacd3bispecificantibodyinpatientswithrelapsedrefractorymultiplemyelomainitialsafetyresultsformagnetismm3 AT mhtomasson p949aphase2trialofelranatamababcellmaturationantigenbcmacd3bispecificantibodyinpatientswithrelapsedrefractorymultiplemyelomainitialsafetyresultsformagnetismm3 AT prodriguezotero p949aphase2trialofelranatamababcellmaturationantigenbcmacd3bispecificantibodyinpatientswithrelapsedrefractorymultiplemyelomainitialsafetyresultsformagnetismm3 AT hquach p949aphase2trialofelranatamababcellmaturationantigenbcmacd3bispecificantibodyinpatientswithrelapsedrefractorymultiplemyelomainitialsafetyresultsformagnetismm3 AT nsraje p949aphase2trialofelranatamababcellmaturationantigenbcmacd3bispecificantibodyinpatientswithrelapsedrefractorymultiplemyelomainitialsafetyresultsformagnetismm3 AT siida p949aphase2trialofelranatamababcellmaturationantigenbcmacd3bispecificantibodyinpatientswithrelapsedrefractorymultiplemyelomainitialsafetyresultsformagnetismm3 AT msraab p949aphase2trialofelranatamababcellmaturationantigenbcmacd3bispecificantibodyinpatientswithrelapsedrefractorymultiplemyelomainitialsafetyresultsformagnetismm3 AT aczibere p949aphase2trialofelranatamababcellmaturationantigenbcmacd3bispecificantibodyinpatientswithrelapsedrefractorymultiplemyelomainitialsafetyresultsformagnetismm3 AT ssullivan p949aphase2trialofelranatamababcellmaturationantigenbcmacd3bispecificantibodyinpatientswithrelapsedrefractorymultiplemyelomainitialsafetyresultsformagnetismm3 AT eleip p949aphase2trialofelranatamababcellmaturationantigenbcmacd3bispecificantibodyinpatientswithrelapsedrefractorymultiplemyelomainitialsafetyresultsformagnetismm3 AT aviqueira p949aphase2trialofelranatamababcellmaturationantigenbcmacd3bispecificantibodyinpatientswithrelapsedrefractorymultiplemyelomainitialsafetyresultsformagnetismm3 AT xleleu p949aphase2trialofelranatamababcellmaturationantigenbcmacd3bispecificantibodyinpatientswithrelapsedrefractorymultiplemyelomainitialsafetyresultsformagnetismm3 |